ALUMIS INC Share Price Today: Live Updates & Key Insights

ALUMIS INC share price today is $24.78, up -4.97%. The stock opened at $25.8 against the previous close of $26.34, with an intraday high of $26.04 and low of $24.91.

ALUMIS INC Share Price Chart

ALUMIS INC

us-stock
To Invest in {{usstockname}}
us-stock

ALUMIS INC Share Price Performance

$24.78 -0.0497(-4.97%) ALMS at 13 Mar 2026 11:57 AM Biotechnology
Lowest Today 24.91
Highest Today 26.04
Today’s Open 25.8
Prev. Close 26.34
52 Week High 30.60
52 Week Low 2.76
Day’s Range: Low 24.91 High 26.04
52-Week Range: Low 2.76 High 30.60
1 day return -
1 Week return -7.02
1 month return -5.8
3 month return +121.03
6 month return +471.0
1 year return +442.51
3 year return -
5 year return -
10 year return -

ALUMIS INC Institutional Holdings

ALUMIS INC Market Status

Strong Buy: 4

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

ALUMIS INC Fundamentals

Market Cap 3284.36 M

PB Ratio 9.1062

PE Ratio 0.0

Enterprise Value 2944.43 M

Total Assets 340.99 M

Volume 1397560

ALUMIS INC Company Financials

Annual Revenue FY23:0 0.0M

Annual Profit FY23:null 0.0M

Annual Net worth FY23:-154993000 -155.0M

Quarterly Revenue Q3/2025:2066000 2.1M, Q2/2025:2666000 2.7M, Q1/2025:17389000 17.4M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:2066000 2.1M, Q2/2025:2666000 2.7M, Q1/2025:17389000 17.4M, Q3/2024:null 0.0M, Q2/2024:-760000 -0.8M

Quarterly Net worth Q3/2025:-110752000 -110.8M, Q2/2025:59321000 59.3M, Q1/2025:-98963000 -99.0M, Q3/2024:-93117000 -93.1M, Q2/2024:-56508000 -56.5M

About ALUMIS INC & investment objective

Company Information Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

Organisation Biotechnology

Employees 221

Industry Biotechnology

CEO Mr. Martin Babler Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right